eMedicine Specialties > Emergency Medicine > Warfare - Chemical, Biological, Radiological, Nuclear and Explosives

CBRNE - Viral Hemorrhagic Fevers

Author: David C Pigott, MD, Associate Professor, Department of Emergency Medicine, University of Alabama at Birmingham
Contributor Information and Disclosures

Updated: May 29, 2009

Introduction

Background

Viral hemorrhagic fevers (VHFs) are a group of febrile illnesses caused by RNA viruses from several viral families. These highly infectious viruses lead to a potentially lethal disease syndrome characterized by fever, malaise, vomiting, mucosal and gastrointestinal (GI) bleeding, edema, and hypotension. The 4 viral families known to cause VHF disease in humans include the Arenaviridae, Bunyaviridae, Filoviridae, and Flaviviridae. General characteristics of these viral families can be found in the table below.Table 1. Viral Families Causing Viral Hemorrhagic Fever

Open table in new window

Table
Virus FamilyDisease (Virus)Natural DistributionUsual Source of Human InfectionIncubation (Days)
Arenaviridae
ArenavirusLassa feverAfricaRodent5-16
Argentine HF (Junin)South AmericaRodent7-14
Bolivian HF (Machupo)South AmericaRodent9-15
Brazilian HF (Sabia)South AmericaRodent7-14
Venezuelan HF (Guanarito)South AmericaRodent7-14
Bunyaviridae
PhlebovirusRift Valley feverAfricaMosquito2-5
NairovirusCrimean-Congo HFEurope, Asia, AfricaTick3-12
HantavirusHemorrhagic fever with renal syndrome, hantavirus pulmonary syndromeAsia, Europe, worldwideRodent9-35
Filoviridae
FilovirusMarburg and EbolaAfricaUnknown3-16
Flaviviridae
FlavivirusYellow feverTropical Africa, South AmericaMosquito3-6
Dengue HFAsia, Americas, AfricaMosquitoUnknown for dengue HF, 3-5 for dengue
Virus FamilyDisease (Virus)Natural DistributionUsual Source of Human InfectionIncubation (Days)
Arenaviridae
ArenavirusLassa feverAfricaRodent5-16
Argentine HF (Junin)South AmericaRodent7-14
Bolivian HF (Machupo)South AmericaRodent9-15
Brazilian HF (Sabia)South AmericaRodent7-14
Venezuelan HF (Guanarito)South AmericaRodent7-14
Bunyaviridae
PhlebovirusRift Valley feverAfricaMosquito2-5
NairovirusCrimean-Congo HFEurope, Asia, AfricaTick3-12
HantavirusHemorrhagic fever with renal syndrome, hantavirus pulmonary syndromeAsia, Europe, worldwideRodent9-35
Filoviridae
FilovirusMarburg and EbolaAfricaUnknown3-16
Flaviviridae
FlavivirusYellow feverTropical Africa, South AmericaMosquito3-6
Dengue HFAsia, Americas, AfricaMosquitoUnknown for dengue HF, 3-5 for dengue

Arenaviridae

Arenaviridae are spread to humans by rodent contact and include Lassa virus in Africa and several rare South American hemorrhagic fevers such as Machupo, Junin, Guanarito, and Sabia. Lassa virus is the most clinically significant of the Arenaviridae, accounting for serious morbidity and mortality in West Africa.

Lassa fever first appeared in Lassa, Nigeria, in 1969. It has been found in all countries of West Africa and is a significant public health problem in endemic areas. In populations studied, Lassa fever accounts for 5-14% of hospitalized febrile illnesses. Its natural reservoir is a small rodent whose virus-containing excreta is the source of transmission.


<EM>Mastomys</EM> rodent, natural host of Lassa v...

Mastomys rodent, natural host of Lassa virus. Image courtesy of the Centers for Disease Control and Prevention.

<EM>Mastomys</EM> rodent, natural host of Lassa v...

Mastomys rodent, natural host of Lassa virus. Image courtesy of the Centers for Disease Control and Prevention.



Bunyaviridae

This group includes Rift Valley fever (RVF) virus, Crimean-Congo hemorrhagic fever (CCHF) virus, and several hantaviruses. The RVF and CCHF viruses are both arthropod-borne viruses. RVF virus, an important African pathogen, is transmitted to humans and livestock by mosquitos and by the slaughter of infected livestock. CCHF virus is carried by ticks and causes a fulminant, highly pathogenic form of VHF notable for aerosol transmission of infective particles. Outbreaks of CCHF have occurred in Africa, Asia, and Europe.


Bunyavirus infection. Ecchymoses encompassing lef...

Bunyavirus infection. Ecchymoses encompassing left upper extremity one week after onset of CCHF. Ecchymoses often are accompanied by hemorrhage in other locations: epistaxis, puncture sites, hematemesis, melena, and hematuria. Image provided by Robert Swaneopoel, PhD, DTVM, MRCVS, National Institute of Virology, Sandringham, South Africa.

Bunyavirus infection. Ecchymoses encompassing lef...

Bunyavirus infection. Ecchymoses encompassing left upper extremity one week after onset of CCHF. Ecchymoses often are accompanied by hemorrhage in other locations: epistaxis, puncture sites, hematemesis, melena, and hematuria. Image provided by Robert Swaneopoel, PhD, DTVM, MRCVS, National Institute of Virology, Sandringham, South Africa.



Many hantaviruses are spread worldwide, causing 2 major syndromes: hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS). They are divided into Old World hantaviruses (such as the prototypical Hantaan virus of Korea), which generally cause HFRS, and New World hantaviruses, causing HPS. Rodents carry both types. A previously undiscovered Hantavirus, Sin Nombre virus, was the cause of an outbreak of highly lethal HPS in the southwestern US in 1993.

Filoviridae

The most notorious of the VHF viruses, including Ebola and Marburg viruses, belong to the Filoviridae family. Ebola virus first was described in 1976 after outbreaks of a febrile, rapidly fatal hemorrhagic illness were reported along the Ebola River in Zaire (now the Democratic Republic of the Congo) and Sudan. Sporadic outbreaks have continued since that time, usually in isolated areas of central Africa. An outbreak in Kikwit, Zaire, in 1995 led to 317 confirmed cases, with an 81% mortality rate. Two thirds of the patients were among health care workers caring for infected individuals. An outbreak in Uganda in late 2000 resulted in 425 cases and claimed 225 lives.

In September 2007, the cause of a VHF outbreak in the Congo was identified as Ebola. Ebola has 4 distinct subtypes: Ebola-Zaire, Ebola-Sudan, Ebola-Ivory Coast, and Ebola-Reston, a form that causes illness in nonhuman primates, and as has been recently discovered, in pigs.1 A 2007 Ebola outbreak in Uganda, however, has been attributed to a new form of Ebola. This new Ebola subtype, which appears to be closely related to Ebola-Ivory Coast, has been given the proposed name Bundibugyo Ebola virus (named after the Bundibugyo district in Western Uganda).2

The natural reservoir of Ebola virus remains unknown, although some recent studies have suggested that bats may be a potential reservoir for Ebola.3


Ebola virus. Electron micrograph courtesy of the ...

Ebola virus. Electron micrograph courtesy of the Centers for Disease Control and Prevention.

Ebola virus. Electron micrograph courtesy of the ...

Ebola virus. Electron micrograph courtesy of the Centers for Disease Control and Prevention.



Marburg virus, named after the German town where it first was reported in 1967, is another highly pathogenic member of the Filoviridae family that is traced to central Africa. As in Ebola, the natural host for the virus is unknown. Marburg virus was contracted by a traveler to central Africa in 1987 and has been endemic since 1998 in Durba, Democratic Republic of the Congo, and in persons exposed in gold mines. Marburg virus was determined to be the causative agent in a 2004-2005 outbreak of hemorrhagic fever in Angola that led to 252 confirmed cases and 227 deaths (90% case-fatality rate).


Marburg virus. Negative stain image courtesy of t...

Marburg virus. Negative stain image courtesy of the Centers for Disease Control and Prevention.

Marburg virus. Negative stain image courtesy of t...

Marburg virus. Negative stain image courtesy of the Centers for Disease Control and Prevention.



Flaviviridae

Yellow fever and dengue fever are the most well known diseases caused by flaviviruses. Both are mosquito-borne; yellow fever is found in tropical Africa and South America, and dengue fever is found in Asia, Africa, and the Americas. They are notable for their significant effect on prior military campaigns and their continued presence throughout endemic areas.

Pathophysiology

The primary defect in patients with viral hemorrhagic fever (VHF) is that of increased vascular permeability. Hemorrhagic fever viruses have an affinity for the vascular system, leading initially to signs such as flushing, conjunctival injection, and petechial hemorrhages, usually associated with fever and myalgias. Later, frank mucous membrane hemorrhage may occur, with accompanying hypotension, shock, and circulatory collapse. The relative severity of the clinical presentation may vary depending on the virus in question, amount, and route of exposure.

In acute disease, patients are extremely viremic, and messenger ribonucleic acid (mRNA) evidence of multiple cytokine activation exists. In vitro studies reveal these cytokines lead to shock and increased vascular permeability, the basic pathophysiologic processes most often seen in viral hemorrhagic fever infection. Another prominent pathologic feature is pronounced macrophage involvement. Inadequate or delayed immune response to these novel viral antigens may lead to rapid development of overwhelming viremia. Extensive infection and necrosis of affected organs also are described. Hemorrhagic complications are multifactorial and are related to hepatic damage, consumptive coagulopathy, and primary marrow injury to megakaryocytes. Aerosol transmission of some viral hemorrhagic fever infections is reported among nonhuman primates and likely is a mode of transmission in patients with severe infection.

Multisystem organ failure affecting the hematopoietic, neurologic, and pulmonary systems often accompanies the vascular involvement. Hepatic involvement varies with the infecting organism and is at times seen with Ebola, Marburg, RVF, CCHF, and yellow fever. Renal failure with oliguria is a prominent feature of HFRS seen in Hantavirus infection and may be seen in other VHFs as intravascular volume depletion becomes more pronounced. Bleeding complications are particularly prominent with Ebola, Marburg, CCHF, and the South American arenaviruses.

Frequency

United States

Cases of viral hemorrhagic fever in the United States are extremely rare and usually are found in patients who recently have visited endemic areas or among those with potential occupational exposure to hemorrhagic fever viruses. Lassa fever has been reported in the United States in travelers from West Africa and was most recently reported in the United States in August 2004. In 1994, a virologist working with Sabia, a Brazilian HF virus, accidentally contracted the disease. Sporadic cases of HPS due to Sin Nombre virus continue to be reported throughout the southwestern United States.4

No human cases of Ebola or Marburg virus disease have been reported in the United States. In 1989, an outbreak of hemorrhagic fever among imported macaque monkeys in Reston, Virginia, led to the discovery of Ebola-Reston, a variant of Ebola virus that originated in the Philippines and does not cause disease in humans.

International

Lassa fever is responsible for an estimated 100,000-300,000 infections per year, with 5,000 deaths. Cases have been reported throughout West Africa, particularly in Nigeria, Sierra Leone, Guinea, and Liberia. Other arenaviruses are responsible for sporadic VHF outbreaks throughout South America.

Rift Valley fever (RVF) virus and Crimean-Congo hemorrhagic fever (CCHF) are responsible for intermittent epidemics in Africa (for RVF) and in areas of Africa, Asia, and Europe (for CCHF). HFRS due to Hantavirus infection continues to be an ongoing health concern, particularly in Asia, affecting up to 200,000 patients annually.

Ebola virus appears sporadically in endemic areas of the former Zaire and Sudan. Ebola virus also has been reported in Gabon, the Ivory Coast, and Uganda. Outbreaks appear to propagate in hospital settings, often involving health care providers.

Yellow fever continues to be a serious problem in tropical areas of South America and Africa, where vaccination is not widespread. The World Health Organization estimates that approximately 200,000 cases per year occur in Africa. Dengue HF is endemic in Southeast Asia, and more than 1 million cases occur annually.

Mortality/Morbidity

Case-fatality rates of patients with VHF vary from less than 10% (eg, in dengue HF) to approximately 90%, as has been reported in patients with Ebola-Zaire and the recent Angola Marburg outbreak. The most recent outbreak of Ebola-Sudan in Uganda had a 50% case-fatality rate.

Complications from VHF infection include retinitis, orchitis, hepatitis, transverse myelitis, and uveitis. In patients who recover from Lassa fever infection, deafness is the most common complication. Spontaneous abortion also is common. Renal insufficiency is associated with HFRS infection.

Race

No racial predilection has been identified, although cases have originated in African areas.

Sex

No predilection for either sex has been identified.

Age

VHF affects all ages according to exposure and local demographics.

Clinical

History

  • Obtain a detailed travel history, paying particular attention to recent travel to tropical or rural areas, such as Central or South America (yellow fever, arenaviruses), West Africa (Lassa fever), or to endemic portions of Central Africa (Ebola, Marburg, RVF, CCHF). Ask about contact with potential arthropod or rodent reservoirs.
    • Since the natural reservoir for Ebola and Marburg viruses is unknown, contact with infected monkeys or humans is not a prerequisite for transmission of infection.
    • Direct contact with rodents infected with hemorrhagic fever viruses (eg, arenaviruses, hantaviruses) is not necessary for transmission of infection, since aerosolized excreta may transmit infection.
  • Contacts of patients with known viral hemorrhagic fever (VHF), especially family members or health care workers caring for infected patients, are at risk for infection if appropriate barrier precautions are not used.
    • Transmission of VHF has occurred from the reuse of unsterile needles and syringes used for treatment of infected patients.
    • Transmission of VHF also has occurred to individuals handling the deceased in preparation for burial or to individuals involved in the slaughter of infected livestock (as in RVF or CCHF).
  • Because of their extreme pathogenicity and potential for transmission by fine particle aerosol, VHF viruses are considered potential biological warfare agents. In addition, Dr Ken Alibek, the former Deputy Director of the once massive Soviet bioweapons program, Biopreparat, claims Soviet scientists successfully had produced a stable Marburg virus biological weapon that could be delivered as an aerosol.
    • Large numbers of military personnel with VHF symptoms suggest such an attack.
    • An outbreak of VHF in a nonendemic area also suggests a biological warfare attack.
  • Incubation periods for VHF vary from 2-21 days.
  • The initial symptoms correspond to development of viremia and include the following:
    • High fever
    • Headache
    • Fatigue
    • Abdominal pain
    • Myalgias
    • Prostration
  • In more advanced disease, signs and symptoms include the following:
    • Hematemesis and bloody diarrhea
    • Generalized mucous membrane hemorrhage
    • Rash
    • Altered mental status and cardiovascular collapse (preterminal events)

Physical

Depending on the progress of the disease, patients with viral hemorrhagic fever (VHF) initially may present with minimal signs, suggesting a more benign viral syndrome. Maintain a high index of suspicion. As the disease progresses, more classic findings are present as follows:

  • Fever
  • Pharyngitis
  • Conjunctival injection
  • Nondependent edema
  • Petechial or ecchymotic rash
  • GI bleeding
  • Hypotension and/or shock
  • Most hemorrhagic fevers, except Rift Valley fever, can produce a variety of cutaneous findings that are principally caused by vascular instability and bleeding abnormalities. Such findings include flushing, petechiae, purpura, ecchymoses, and edema.
  • The Old World arenavirus causing Lassa fever results in the greatest amount of edema of any of the hemorrhagic fever viruses. Additionally, no bleeding abnormalities are present.
  • The New World arenaviruses (Junin, Machupo, Sabia, and Guanarito) cause less edema and variable amounts of petechiae, purpura, ecchymoses, palatal hyperemia, and mucosal hemorrhage.
  • The most severe hemorrhage from a hemorrhagic fever virus follows infection with the Congo Crimean hemorrhagic fever virus.
  • Hantaviruses can cause a relatively distinctive eruption with a petechial eruption around the neck and on the anterior and posterior axillary folds, arms, and trunk. A sunburn-like flush is seen on the head, neck, and upper chest and back and may be accompanied by facial edema. Sometimes, a morbilliform eruption occurs. Oral and conjunctival surfaces may develop severe hemorrhages.


Bunyavirus infection - Hantaan virus. Patient wit...

Bunyavirus infection - Hantaan virus. Patient with Korean hemorrhagic fever caused by Hantaan virus demonstrating typical 'sunburn flush' of cheeks, chin, and base of neck. Photo courtesy of John Huggins, PhD.

Bunyavirus infection - Hantaan virus. Patient wit...

Bunyavirus infection - Hantaan virus. Patient with Korean hemorrhagic fever caused by Hantaan virus demonstrating typical 'sunburn flush' of cheeks, chin, and base of neck. Photo courtesy of John Huggins, PhD.

  • The greatly feared filoviruses (Marburg and Ebola) exhibit characteristic exanthems that are best seen in fair-skinned patients. Soft palatal hyperemia accompanies the flu-like prodrome and is followed between days 5 and 7 by a nonpruritic, centripetal, pinhead-sized papular, erythematous exanthem. Within 24 hours, this can develop into large and coalescent, well-demarcated, sometimes hemorrhagic macules and papules. In severe cases, hemorrhage exudes from mucous membranes, venipuncture sites, and body orifices.
  • Dengue virus causes a characteristic erythematous exanthem with striking islands of sparing.


Patient with morbilliform exanthem of dengue feve...

Patient with morbilliform exanthem of dengue fever. Note islands of sparing characteristics for dengue. Photo courtesy Duane Gubler, PhD.

Patient with morbilliform exanthem of dengue feve...

Patient with morbilliform exanthem of dengue fever. Note islands of sparing characteristics for dengue. Photo courtesy Duane Gubler, PhD.

Causes

More on CBRNE - Viral Hemorrhagic Fevers

Overview: CBRNE - Viral Hemorrhagic Fevers
Differential Diagnoses & Workup: CBRNE - Viral Hemorrhagic Fevers
Treatment & Medication: CBRNE - Viral Hemorrhagic Fevers
Follow-up: CBRNE - Viral Hemorrhagic Fevers
Multimedia: CBRNE - Viral Hemorrhagic Fevers
References

References

  1. Normile D. Emerging infectious diseases. Scientists puzzle over Ebola-Reston virus in pigs. Science. Jan 23 2009;323(5913):451. [Medline].

  2. Towner JS, Sealy TK, Khristova ML, Albarino CG, Conlan S, Reeder SA, et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog. Nov 2008;4(11):e1000212. [Medline].

  3. Leroy EM, Epelboin A, Mondonge V, Pourrut X, Gonzalez JP, Muyembe-Tamfum JJ, et al. Human Ebola Outbreak Resulting from Direct Exposure to Fruit Bats in Luebo, Democratic Republic of Congo, 2007. Vector Borne Zoonotic Dis. Mar 26 2009;[Medline].

  4. Rivers MN, Alexander JL, Rohde RE, Pierce JR Jr. Hantavirus pulmonary syndrome in Texas: 1993-2006. South Med J. Jan 2009;102(1):36-41. [Medline].

  5. Tuffs A. Experimental vaccine may have saved Hamburg scientist from Ebola fever. BMJ. Mar 23 2009;338:b1223. [Medline].

  6. Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Stroher U, Grolla A. Effective post-exposure treatment of Ebola infection. PLoS Pathog. Jan 2007;3(1):e2. [Medline].

  7. Borchert M, Muyembe-Tamfum JJ, Colebunders R, et al. Short communication: a cluster of Marburg virus disease involving an infant. Trop Med Int Health. Oct 2002;7(10):902-6. [Medline].

  8. CDC. Imported Lassa fever--New Jersey, 2004. MMWR Morb Mortal Wkly Rep. Oct 1 2004;53(38):894-7. [Medline].

  9. CDC. Outbreak of Ebola hemorrhagic fever Uganda, August 2000-January 2001. MMWR Morb Mortal Wkly Rep. Feb 9 2001;50(5):73-7. [Medline].

  10. CDC. Update: management of patients with suspected viral hemorrhagic fever--United States. MMWR Morb Mortal Wkly Rep. 1995;44(25):475-9. [Medline][Full Text].

  11. Colebunders R, Borchert M. Ebola haemorrhagic fever--a review. J Infect. 2000;40(1):16-20. [Medline].

  12. Fisher-Hoch SP, Hutwagner L, Brown B, McCormick JB. Effective vaccine for lassa fever. J Virol. 2000;74(15):6777-83. [Medline][Full Text].

  13. Fisher-Hoch SP, McCormick JB. Lassa fever vaccine. Expert Rev Vaccines. Apr 2004;3(2):189-97. [Medline].

  14. Geisbert TW, Daddario-Dicaprio KM, Geisbert JB, Reed DS, Feldmann F, Grolla A, et al. Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses. Vaccine. Dec 9 2008;26(52):6894-900. [Medline].

  15. Geisbert TW, Hensley LE. Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev Mol Med. Sep 21 2004;6(20):1-24. [Medline].

  16. Geisbert TW, Jahrling PB. Towards a vaccine against Ebola virus. Expert Rev Vaccines. Dec 2003;2(6):777-89. [Medline].

  17. Holmes GP, McCormick JB, Trock SC, et al. Lassa fever in the United States. Investigation of a case and new guidelines for management. N Engl J Med. 1990;323(16):1120-3. [Medline].

  18. Jahrling PB. Viral hemorrhagic fevers. In: Textbook of Military Medicine: Medical Aspects of Chemical and Biological Warfare. 1997.

  19. Leroy EM, Kumulungui B, Pourrut X, Rouquet P, Hassanin A, Yaba P. Fruit bats as reservoirs of Ebola virus. Nature. Dec 1 2005;438(7068):575-6. [Medline].

  20. Mahanty S, Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect Dis. Aug 2004;4(8):487-98. [Medline].

  21. McGovern TW, Christopher GW, Eitzen EM. Cutaneous manifestations of biological warfare and related threat agents. Arch Dermatol. Mar 1999;135(3):311-22. [Medline].

  22. Peters CJ, LeDuc JW. Ebola: the virus and the disease. J Infect Dis. 1999;179 (Suppl 1):ix-xvi. [Medline][Full Text].

  23. Ströher U, Feldmann H. Progress towards the treatment of Ebola haemorrhagic fever. Expert Opin Investig Drugs. Dec 2006;15(12):1523-35. [Medline].

  24. Towner JS, Rollin PE, Bausch DG, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol. Apr 2004;78(8):4330-41. [Medline].

Further Reading

Keywords

viral hemorrhagic fevers, hemorrhagic fever, symptoms, treatment, causes, VHF, Arenaviridae, Bunyaviridae, Filoviridae, Flaviviridae, Lassa fever, Lassa virus, Argentine hemorrhagic fever, Bolivian hemorrhagic fever, Brazilian hemorrhagic fever, Venezuelan hemorrhagic fever, Rift Valley fever, Crimean-Congo hemorrhagic fever, arenavirus, hantavirus, phlebovirus, nairovirus, filovirus, Marburg virus, Ebola virus, flavivirus, yellow fever, dengue, dengue hemorrhagic fever

Contributor Information and Disclosures

Author

David C Pigott, MD, Associate Professor, Department of Emergency Medicine, University of Alabama at Birmingham
David C Pigott, MD is a member of the following medical societies: American College of Emergency Physicians and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Medical Editor

Jerry L Mothershead, MD, Medical Readiness Consultant, Medical Readiness and Response Group, Battelle Memorial Institute; Advisor, Technical Advisory Committee, Emergency Management Strategic Healthcare Group, Veteran's Health Administration; Adjunct Associate Professor, Department of Military and Emergency Medicine, Uniformed Services University of the Health Sciences
Jerry L Mothershead, MD is a member of the following medical societies: American College of Emergency Physicians and National Association of EMS Physicians
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Rick Kulkarni, MD, Medical Director, Assistant Professor of Surgery, Section of Emergency Medicine, Yale-New Haven Hospital
Rick Kulkarni, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: WebMD Salary Employment

CME Editor

John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.

Chief Editor

Robert G Darling, MD, FACEP, Clinical Assistant Professor of Military and Emergency Medicine, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Associate Director, Center for Disaster and Humanitarian Assistance Medicine
Robert G Darling, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, and Association of Military Surgeons of the US
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.